Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HGG-2010 DC vaccine add-on in newly diagnosed glioblastoma
2009-018228-14Phase 2Completed
- Sponsor
- UZ Leuven
- Start
- Apr 2011
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in glioblastoma (GBM) comparing Temozolomide + DCm-HGG-L with Temozolomide + placebo (2 arms). Primary endpoint: Progression-free survival after 6 cycles of temozolomide. Started Apr 2011; status: completed.
02
Drugs
DCm-HGG-L
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on 2009-018228-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-018228-14.